Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It is now 5 years since the UK became the first country to introduce the serogroup C meningococcal polysaccharide-protein conjugate vaccines (MenC) into its routine immunisation schedule. This article reviews the global use of MenC with particular reference to the range of immunisation strategies used internationally. To date, concerns that MenC may result in an increase in meningococcal disease due to non-C serogroups have not been realised. The vaccine has proved to be highly safe and effective; however, concerns have arisen regarding the duration of vaccine effectiveness. Although booster doses of MenC may potentially extend the duration of protection offered by the vaccine, there are, as yet, no studies assessing this option. Clinical trials are underway to assess new combination conjugate vaccines (containing A, C, Y, and W polysaccharides), and it is probable that these more broadly protective vaccines will become available in the near future.

Original publication

DOI

10.1016/S1473-3099(04)01251-4

Type

Journal article

Journal

Lancet Infect Dis

Publication Date

01/2005

Volume

5

Pages

21 - 30

Keywords

Adolescent, Adult, Child, Child, Preschool, Humans, Immunization Programs, Infant, Meningitis, Meningococcal, Meningococcal Vaccines, Neisseria meningitidis, Serogroup C, Serotyping, United Kingdom